As PlGF is upregulated in cancer and stromal cells, it leads to displacement of VEGF from sVEGFR1 and consequently increases its bioavailability and binding to VEGFR2, leading to transmission of proangiogenic signals. The gene discussed is PGF; the disease is cancer.